Acute myeloid leukemia (AML) is a hematological malignancy characterized by the accumulation of immature myeloid precursor cells. AML is poorly responsive to conventional genotoxic chemotherapy and a diagnosis of AML is usually fatal.
Introduction
Acute myeloid leukemia (AML) is a genetically heterogeneous disease that is characterized by the aberrant growth of myeloid progenitor cells with a block in cellular differentiation. AML is the most common adult acute leukemia and comprises 20% of childhood leukemias 1, 2 . AML is an aggressive malignancy and long-term (5 year) survival is less than 50% even for younger patients that can withstand intensive cytotoxic chemotherapy. Outcomes are far worse in elderly and less fit younger patients who can only receive less intensive chemotherapy (median survival < 1 year) 3, 4 . Significant improvement of AML patient outcomes will require the development of new therapeutic strategies that are both more effective and less toxic than currently used regimens. While in recent years there have been significant advances in our understanding of AML biology and the various genetic alterations that drive the disease, this knowledge has not, as of yet, led to development of targeted therapies that are capable of achieving long-term remissions. Moreover, for targeted therapies that have shown some modicum of clinical efficacy, such as those targeting FLT3 and IDH2, their utility is limited to subsets of AML that exhibit mutations in these genes 1, 5, 6 .
It has long been known that tumor cells rewire their metabolism to enable and sustain cell growth and proliferation and reprogrammed cellular metabolism is now recognized as a hallmark of cancer [7] [8] [9] . It is feasible that the unique metabolic dependencies of tumor cells may be targeted for therapeutic effect.
Many types of tumor cells, including AML, are highly dependent on glutamine for glutaminolysis, a mitochondrial pathway that involves the initial deamination of glutamine by the enzyme glutaminase (GLS and GLS2), yielding glutamate, which can then be converted into α-ketoglutarate to fuel the TCA cycle or used as a precursor for synthesis of glutathione, an important antioxidant factor [10] [11] [12] [13] .
Our previous work has shown that inhibition of FLT3 in FLT3-mutated AML shuts down glutamine metabolism, leading to depletion of glutathione and cell death by apoptosis due to overwhelming oxidative stress 14 . In addition, we and others have shown that inhibition of glutaminase in FLT3-mutated AML has similar effects as FLT3 inhibition on glutathione levels, redox state, and cell viability 15, 16 .
In the present study, we sought to determine if glutaminase inhibition could universally compromise glutathione metabolism and redox state in multiple types of AML and thus demonstrate broad therapeutic potential. Indeed, we found that a glutaminase inhibitor (CB-839) inhibits glutathione production, induces mitochondrial reactive oxygen species (mitoROS) and causes apoptotic cell death in many types of AML, as well as in acute lymphoblastic leukemia (ALL) . Moreover, we demonstrate that combining a glutaminase inhibitor with a drug that further induces mitoROS is an effective therapeutic strategy for eliminating leukemia cells both in vitro and in vivo.
Materials and Methods

Cell culture
The 
Metabolic tracing experiments
Cells were seeded at 3 x 10 5 /ml (replicates of 3) and treated with vehicle (DMSO)
or CB-839 at 500 nM for 8 h, followed by incubation in glutamine-free RPMI 1640
supplemented with 13 
Statistics
All data are expressed as the mean ± SEM. Comparisons between two values were performed by Mann Whitney U test, significance was defined at P ≤ 0.05 *, P ≤ 0.01 **. Combination indices were calculated using the median-effect principle and the Combination Index-Isobologram Theorem (CompuSyn).
Results
Our previous studies have shown that impeding glutamine uptake or metabolism using either a FLT3 inhibitor or glutaminase inhibitor, respectively, impairs anti-oxidant defenses by limiting glutathione synthesis and leads to the accumulation of mitochondrial oxidative stress and subsequent apoptosis in FLT3-mutated AML cells 14, 15 . FLT3, however, is mutated in only a subset of AMLs. Thus, we wanted to determine if glutaminase inhibition could similarly impair glutamine/glutathione metabolism in AML cells of other genotypes, indicating the potential for broader therapeutic utility. To this end, we employed metabolic flux analysis using 13 C, 15 N-labeled glutamine ( Figure S1A ) in two FLT3
wild type (WT) AML cell lines, OCI-AML3 and EOL-1. These cells were treated with vehicle or the glutaminase inhibitor CB-839 for 8 h hollowed followed by incubation with labeled glutamine (up to 12 h). As shown in Figure 1A , the cells treated with CB-839 displayed severe impairment of glutamine flux into glutamate and its downstream metabolites aspartate, alanine and α-ketoglutarate. Since α-ketoglutarate feeds into the tricarboxylic (TCA) cycle, flux into TCA cycle intermediates (succinate, malate, and citrate) was severely reduced. As was previously observed in FLT3 mutated AML, CB-839 also impaired flux into antioxidant glutathione, leading to lower overall glutathione levels ( Figure S1B ).
The depletion of α-ketoglutarate and glutathione could both contribute to CB-839-induced apoptosis, through energy (ATP) depletion due to TCA cycle interference and/or through oxidative stress due to lack of anti-oxidant capacity.
In attempt to parse the importance of the TCA cycle for cell survival, we added dimethyl-glutarate to EOL-1 cells upon treatment with CB-839. Dimethylglutarate is a membrane-permeable dimethyl-ester of α-ketoglutarate (α-KG), which is metabolized to α-KG by cellular esterases. As shown in Figure In order to test the therapeutic strategy described above, we first tested the efficacy of arsenic trioxide (ATO) combined with CB-839 on AML cell lines in vitro. ATO is an agent that promotes generation of ROS and mitochondrial apoptosis, and it has long been known to have anti-leukemic activity 22 . As shown in Figure 3A , ATO by itself induces mitoROS in a dose-dependent manner; however, ATO induces higher levels of mitoROS when used in combination with CB-839. Moreover, ATO and CB-839 synergized in killing EOL-1 cells ( Figure 3B ). Combination index (CI) values were synergistic (< 0.6) at all combination doses tested and were strongly synergistic (< 0.3) with most combinations (all CI values listed in Table S1 ). Effects on viability correlated with increased apoptosis ( Figure 3C ). Comparable results were obtained using Molm13 cells; while ATO did not induce appreciable mitoROS in these cells by itself, it strongly induced mitoROS when used in combination with CB-839 ( Figure 3D ), which correlated with increased cell killing ( Figure 3E ) and apoptosis ( Figure 3F ). This drug combination had similar effects on cell viability and apoptosis in several additional AML cell lines, including OCI-AML3, MV4-11, KG1a, HL-60, and MonoMac6 ( Figures S3A-F Leukemic burden was quantified using bioluminescent imaging on days 4 and 11 after the start of therapy ( Figure 4A ). By day 11, leukemic burden was significantly lower in the combination treated mice compared to the groups treated with either ATO or CB-839 alone ( Figure 4A and B), indicating superior therapeutic efficacy.
To determine if CB-839 will effectively combine with another drug that induces mitochondrial ROS, we next explored homoharringtonine (HHT). HHT is a protein translation inhibitor indicated for the treatment of tyrosine kinase inhibitor-resistant CML 23 that was recently found to effectively combine with FLT3 inhibitors for the treatment of AML 24 . We have previously shown that drugs that combine well with FLT3 inhibitors are frequently potent inducers of mitoROS 14 . Indeed, we found that HHT strongly induced mitoROS in Molm13 AML cells and mitoROS was exacerbated when HHT was used in combination with CB-839 ( Figure 5A ). In addition, HHT synergized with CB-839 in killing
Molm13 cells ( Figure 5B ), which correlated with induction of apoptosis ( Figure   5C ). Similar effects on cell viability using this drug combination were observed in EOL-1 cells ( Figure 5D ). To test efficacy in vivo, we utilized the MLL-ENL/FLT3-ITD AML mouse model described above. Five days after leukemia transfer, therapy was initiated using vehicle, CB-839, HHT, or CB-839 and HHT in combination (n=5 per group). As shown in Figure 5E , Figure 7D shows that while CB-839 by itself had no significant effect, HHT in combination with CB-839 was far more effective than HHT alone in controlling leukemic burden (as shown on days 7 and 10), which resulted in significant extension of survival ( Figure 7E ). Taken all together, these results strongly argue that the strategy of combining a glutaminase inhibitor, such as CB-839, together with a pro-oxidant drug, such as HHT or ATO, has substantial therapeutic potential for treating multiple types of leukemia.
Discussion
It has long been recognized that tumor cells exhibit metabolic characteristics that distinguish them from normal differentiated non-proliferative cells [7] [8] [9] . The altered glucose metabolism that is frequently observed in tumors has been extensively studied and is already being exploited for cancer therapy 25 .
Altered glutamine metabolism in cancer, however, has only recently begun to be investigated. Glutamine is the most abundant amino acid in plasma and most tumors utilize glutamine at a much higher rate compared to normal cells.
Glutamine metabolism contributes to energy production, macromolecular synthesis, and redox homeostasis, and is essential for survival of some cancer cells that have become addicted to glutamine 10, 11, 26 .
Several recent studies have shown that targeting glutamine uptake or metabolism can have anti-leukemic activity in AML 13, 15, 16, 27, 28 . However, most of these studies have focused on the role of glutamine in supporting energy metabolism rather on its role in maintaining redox homeostasis. Our recent studies of FLT3-mutated AML have shown that inhibition of FLT3 severely impairs glutamine metabolism, which leads to a deficiency in glutathione levels and accumulation of mitoROS that is causative in apoptotic cell death 14 . Similar effects were observed in FLT3-mutated AML cells upon direct inhibition of glutaminase 15 . In this report, we show that a glutaminase inhibitor causes decreased glutathione levels and increased mitoROS and apoptosis in an array of different AML cell lines, including those that are FLT3 WT. Furthermore, we
show that addition of exogenous glutathione, which has no effect on energy production, is sufficient to suppress mitoROS levels and apoptosis upon glutaminase inhibition, strongly arguing that glutathione-dependent redox homeostasis is critical for maintaining cell survival in AML. Importantly, this dependence on glutamine/redox metabolism is independent of FLT3 status, and 
